Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 113 first isolates · ICU · Skin / wound infection · 2024-03-31 → 2025-03-30
Intensive care unitNo single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
meropenem 50 % (41 %–59 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (94 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious
diseases if the patient is severely ill.
Not covered: Staphylococcus aureus (37 %), Enterococcus faecalis (12 %), Pseudomonas aeruginosa (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
mecillinam MEC
not for this site0 %
0 %
n = 9
trimethoprim TMP
not for this site0 %
0 %
n = 9
nitrofurantoin NIT
not for this site0 %
0 %
n = 9
Most likely organisms for this profile
Staphylococcus aureus
37 %
Escherichia coli
14 %
Pseudomonas aeruginosa
14 %
Enterococcus faecalis
12 %
Proteus mirabilis
10 %
Klebsiella pneumoniae
7 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.